IMMURON Ltd. ADR (IMROY)

[Renee]

IMROY moved to the NYSE from the OTC:

http://otce.finra.org/DLDeletions

[GS1]

Welcome to Immuron Limited
http://www.immuron.com/

Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, arthritis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in thier pathogenesis. These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile.

Immuron has one marketed product, which provides proof of concept for its Oral Immune Technology Platform, and a pipeline of products at various stages of clinical and earlier development. Immuron’s marketed product, Travelan, is for the prevention of travellers’ diarrhoea. Travelan is a non-absorbable, safe product which is composed of anti-bacterial antibodies that work on the gut immune system and gut microbiome. Travelan has been proven in Clinical studies to offer over 90% protection against Travellers' Diarrhoea and is therefore a major new breakthrough when travelling to high risk destinations. The product is licensed in Australia, in Canada, South African and Latin America, as well as a number of countries in South East Asia.

Immuron Limited Highlights
Positive Phase I data for NASH with potential indication for Diabetes.
http://www.immuron.com/assets/Uploads/AASLD-Poster-2010-NASH-clinical-trial-final.pdf
Currently two Phase II ongoing for NASH and ASH.
ASH and Pediatric NASH trials are fully funded by NIH.
Signed collaboration with US Army for Diarrhoea related products.
Clinical Data readout for NASH Phase II is Mid-2017.
Huge Market opportunity.
30 Billion for NASH.
1-2 Billion for ASH and
500 Million for Pediatric NASH (Phase II trial to Begin Third Qtr 2016).
Travelan Generates 1-2 million in revenue and could reach 30 Million in 4-5 years.
Travelan Launched in US, Canada and more recently in China. Partenering with CVS for distribution.

NASH companies have average market cap of 100-200 mil that are in phase II. With positive phase II data Market cap would be worth Billions of dollars.

See through equity report : Price target $1.37
http://www.immuron.com/assets/IMC-AX-INITIATION-2-2-16-FINAL.PDF

CEO Interview
http://www.redchip.com/events/9/small-stocks-big-money-investor-conference/imc.ax

Company News
http://www.otcmarkets.com/stock/IMROY/news

[GS1]

CEO Interview

[GS1]

IMROY < NASH - ASH >

http://www.immuron.com/assets/IMC-AX-INITIATION-2-2-16-FINAL.PDF

NAFLD Market size - 40 BILLION by 2027